Comparison of Paclitaxel- and Sirolimus-Eluting Stents in Everyday Clinical Practice (SORT OUT II)
日常临床试验中Paclitaxel和Sirolimus-Eluting Stents的比较

Description
The goal of this trial was to evaluate symptom-driven clinical endpoints among unselected patients from the use of sirolimus-eluting stents, compared with paclitaxel-eluting stents.

Hypothesis
One type of drug-eluting stent may be more effective and safer than the other type in treating patients with obstructive coronary artery disease.

Drugs/Procedures Used
Among 11,766 patients undergoing percutaneous coronary intervention (PCI) who were eligible for study participation, 9,668 were excluded due to selection criteria. This resulted in 2,098 randomized patients (1,056 patients received sirolimus-eluting stents and 1,033 patients received paclitaxel-eluting stents).

Principal Findings
The index diagnosis was stable angina in 45%, non-ST-elevation acute coronary syndrome in 33%, and ST-elevation myocardial infarction in 17%. There was one vessel treated in 78% of the patients, two vessels treated in 18%, and three vessels treated in 3%. Type C lesions were treated in 61%. The primary composite outcome occurred in 10% of the sirolimus group and 11.6% of the paclitaxel group (p = 0.21). There was no difference in cardiac death (1.7% vs. 1.5%, p = 0.80), acute myocardial infarction (4.2% vs. 5.1%, p = 0.32), target lesion revascularization (4.5% vs. 5.9%, p = 0.14), target vessel revascularization (6.6% vs. 7.8%, p = 0.25), or stent thrombosis (2.6% vs. 2.8%, p = 0.70) for sirolimus compared with paclit